Abstract:Background Glymphatic dysfunction is a crucial pathway for dementia. Alzheimer’s disease (AD) pathologies co-existing with cerebral small vessel disease (CSVD) is the most common pathogenesis for dementia. We hypothesize that AD pathologies and CSVD could be associated with glymphatic dysfunction, contributing to cognitive impairment. Method Participants completed with amyloid PET, diffusion tensor imaging (DTI), and T2 fluid-attenuated inversion-recovery (FLAIR) sequences were included from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). White matter hyperintensities (WMH), the most common CSVD marker, was evaluated from T2FLAIR images and represented the burden of CSVD. Amyloid PET was used to assess Aβ aggregation in the brain. We used diffusion tensor image analysis along the perivascular space (DTI-ALPS) index, the burden of enlarged perivascular spaces (PVS), and choroid plexus volume to reflect glymphatic function. The relationships between WMH burden/Aβ aggregation and these glymphatic markers as well as the correlations between glymphatic markers and cognitive function were investigated. Furthermore, we conducted mediation analyses to explore the potential mediating effects of glymphatic markers in the relationship between WMH burden/Aβ aggregation and cognition. Results One hundred and thirty-three participants along the AD continuum were included, consisting of 40 CN − , 48 CN + , 26 MCI + , and 19 AD + participants. Our findings revealed that there were negative associations between whole-brain Aβ aggregation ( r = − 0.249, p = 0.022) and WMH burden ( r = − 0.458, p < 0.001) with DTI-ALPS. Additionally, Aβ aggregation ( r = 0.223, p = 0.041) and WMH burden ( r = 0.294, p = 0.006) were both positively associated with choroid plexus volume. However, we did not observe significant correlations with PVS enlargement severity. DTI-ALPS was positively associated with memory ( r = 0.470, FDR- p < 0.001), executive function ( r = 0.358, FDR- p = 0.001), visual-spatial ( r = 0.223, FDR- p < 0.040), and language ( r = 0.419, FDR- p < 0.001). Conversely, choroid plexus volume showed negative correlations with memory ( r = − 0.315, FDR- p = 0.007), executive function ( r = − 0.321, FDR- p = 0.007), visual-spatial ( r = − 0.233, FDR- p = 0.031), and language ( r = − 0.261, FDR- p = 0.021). There were no significant correlations between PVS enlargement severity and cognitive performance. In the mediation analysis, we found that DTI-ALPS acted as a mediator in the relationship between WMH burden/Aβ accumulation and memory and language performances. Conclusion Our study provided evidence that both AD pathology (Aβ) and CSVD were associated with glymphatic dysfunction, which is further related to cognitive impairment. These results may provide a theoretical basis for new targets for treating AD.

Contributions of amyloid beta and cerebral small vessel disease in clinical decline

Associations Between APOE Genotype and Cerebral Small-Vessel Disease: a Longitudinal Study

Distinct Cerebral Small Vessel Disease Impairment in Early- and Late-Onset Alzheimer's Disease.

Clinical Predictors of Postmortem Amyloid and Nonamyloid Cerebral Small Vessel Disease in Middle-Aged to Older Adults

Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly

Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia

Alzheimer's disease and neurodegeneration in symptomatic cerebral small vessel disease

Cerebral Small Vessel Disease Burden Predicts Neurodegeneration and Clinical Progression in Prodromal Alzheimer's Disease

The Interaction Between Vascular Risk Factors, Cerebral Small Vessel Disease, and Amyloid Burden in Older Adults

Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease

Associations of Alzheimer's Disease Pathology and Small Vessel Disease with Cerebral White Matter Degeneration: A Tract-Based MR Diffusion Imaging Study.

The Relationship Between Amyloid Pathology, Cerebral Small Vessel Disease, Glymphatic Dysfunction, and Cognition: a Study Based on Alzheimer’s Disease Continuum Participants

White Matter and Hippocampal Volume Predict the Risk of Dementia in Patients with Cerebral Small Vessel Disease: The RUN DMC Study

Inherited risk of dementia and the progression of cerebral small vessel disease and inflammatory markers in cognitively healthy midlife adults: the PREVENT-Dementia study

Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia

Rates of cortical thinning in Alzheimer’s disease signature regions associate with vascular burden but not with β-amyloid status in cognitively normal adults at age 70

Subjective cognitive decline, brain imaging biomarkers, and cognitive functioning in patients with a history of vascular disease: the SMART-Medea study

Structural network changes in cerebral small vessel disease

White matter hyperintensities influence distal cortical β-amyloid accumulation in default mode network pathways

Risk of Nursing Home Admission in Cerebral Small Vessel Disease

Memory decline in elderly with cerebral small vessel disease explained by temporal interactions between white matter hyperintensities and hippocampal atrophy